BioCardia Q2 2024 GAAP EPS $(0.88), Sales $3.000K Miss $50.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
BioCardia (NASDAQ:BCDA) reported Q2 2024 GAAP EPS of $(0.88) and sales of $3.000K, missing the $50.000K estimate by 94%. This represents a 93.02% decrease from the same period last year.
August 13, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioCardia reported a significant miss in both EPS and sales for Q2 2024, with sales down 93.02% YoY and missing estimates by 94%.
The significant miss in both EPS and sales, along with a drastic year-over-year sales decline, is likely to negatively impact BioCardia's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100